Product Images Axtle

This text provides survival probability data in a study labeled "JMDB." It includes information on survival time in months for different groups of patients, illustrated using Kaplan-Meier curves for overall survival. The numbers of patients at risk at various time points are also shown.*

This is a figure showing Kaplan-Meier Curves for Overall Survival in non-squamous NSCLC in a study named JMDB. The text also includes data related to Survival Time in months and the number of patients at risk.*

The text mentions survival probability in a study comparing Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC) in squamous non-small cell lung cancer (NSCLC). Information such as survival times in months and the number of patients at risk over time is included. The data is presented in a Kaplan-Meier curve for overall survival in Study JMDB.*

This data pertains to the survival probability and patients at risk in a study comparing pemetrexed with placebo. The information includes the number of patients at risk over different time intervals in months, presented in the form of Kaplan-Meier curves for overall survival in Study JMEN.*

This text provides data on the survival probability of patients with non-squamous NSCLC in a study comparing Pemetrexed and Placebo. The information includes survival time in months and the number of patients at risk at different time points. The Kaplan-Meier curves for overall survival are also mentioned in the study titled JMEN.*

This is a data showing the survival probability and patients at risk in a study on Squamous NSCLC evaluating Pemetrexed and Placebo. The Kaplan-Meier curves for overall survival are depicted in Figure 6. The data indicates the number of patients at risk at different time intervals for each treatment group.*

This is a statistical analysis of survival probability based on the Kaplan-Meier curves for overall survival in the PARAMOUNT study. It shows the survival time in months for patients treated with Pemetrexed and Placebo, along with the number of patients at risk at different time points.*

This text provides data on the Kaplan-Meier curves for overall survival in a study comparing Pemetrexed + Cisplatin to Cisplatin alone. It shows the survival time in months and the number of patients at risk over various time points. This information can be used to evaluate the effectiveness of the treatment regimens in the study.*

This text appears to be a label providing information about a drug product, specifically a Varnish Area with the code number AP/DRUGS/03/2011. The product is described as pemetrexed for injection with a strength of 100 mg/vial, intended for intravenous use only. It further mentions that it is a sterile single-dose vial and instructs to discard any unused portion. The label also includes an NDC number of 83831-131-01 for identification purposes.*

This text appears to be a label or packaging details for a pharmaceutical product named AXTLE™. It includes information about batch details, barcode, manufacturing information, dosage, administration instructions, storage instructions, and warnings. The product is a sterile single-dose vial for intravenous use containing 100 mg of pemetrexed. It is advised to discard any unused portion after use and store the product at controlled room temperature. The manufacturing details suggest it is made by Awpca Parma, LLG in New Jersey, USA.*

This text provides detailed information about the medication AXTLE™ (pemetrexed) for injection. It includes instructions for reconstitution, dosage, administration, storage conditions, and warnings about the hazardous nature of the drug. The product is a sterile single-dose vial containing 500 mg of pemetrexed. It should be reconstituted with 5% Dextrose Injection and further diluted before use. The storage requirements include controlled room temperature and refrigeration for both reconstituted and infusion solutions. Specific details such as NDC number, manufacturing information, expiration date, and barcode are also provided on the packaging.*